Cell Biolabs Vpk-219-Eco

Description: Lentivirus based on HIV-1 provides a powerful means for gene expression because it can infect both dividing and non-dividing cells. Other 3rd generation lentiviral packaging systems provide a reduced risk of replication-competent virus, but a small risk remains. Our ViraSafe Lentivirus Expression Complete Systems provide a safer method even compared to other 3rd generation expression systems. Overlap with native HIV genes has been reduced much further, thereby substantially reducing the chance of generating replication-competent virus. The system has been engineered so that lentiviral titers remain at the levels of third generation systems. Our Ecotropic Expression Systems assemble lentiviruses with an ecotropic envelope protein which will readily infect only mouse and rat cells via receptor-mediated binding, providing an additional level of safety. However, ecotropic viruses are not as stable upon freezing and will not survive ultracentrifugation procedures.

Description: Traditionally, adeno-associated virus (AAV) particles have been quantified by DNA dot blot or similar procedures. These methods can be time-consuming and suffer from a high degree of inter-assay variability. Our QuickTiter AAV Quantitation Kit uses a proprietary technology to quantify the viral nucleic acid content of AAV preps. The kit can be used with unpurified supernatant of AAV-2 or AAV-DJ, or with purified AAV from any serotype.

Description: An anti-HBVcAg monoclonal coating antibody is adsorbed onto a microtiter plate. HBV core antigen present in the sample or standard binds to the antibodies adsorbed on the plate; a FITC-conjugated mouse anti-HBVcAg antibody is added and binds to the antigen captured by the first antibody. Following incubation and wash steps, a HRP-conjugated mouse anti-FITC antibody is added and binds to the FITC conjugated anti-HBVcAg. Following unbound HRP-conjugated mouse anti-FITC antibody is removed during a wash step, and substrate solution reactive with HRP is added to the wells. A colored product is formed in proportion to the amount of HBV core antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant HBV core antigen and sample concentration is then determined.

Description: An anti-HCVcAg monoclonal coating antibody is adsorbed onto a microtiter plate. HCV core antigen present in the sample or standard binds to the antibodies adsorbed on the plate; a FITC-conjugated mouse anti-HCVcAg antibody is added and binds to the antigen captured by the first antibody. Following incubation and wash steps, a HRP-conjugated mouse anti-FITC antibody is added and binds to the FITC conjugated anti-HCVcAg. Following unbound HRP-conjugated mouse anti-FITC antibody is removed during a wash step, and substrate solution reactive with HRP is added to the wells. A colored product is formed in proportion to the amount of HCV core antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant HCV core antigen and sample concentration is then determined.

Description: An anti-MuLV p30 monoclonal coating antibody is adsorbed onto a microtiter plate. MuLV core antigen (p30) present in the sample or standard binds to the antibodies adsorbed on the plate; an anti-MuLV p30 polyclonal antibody is added and binds to the antigen captured by the first antibody. Following incubation and wash steps, a HRP-conjugated secondary antibody is added and binds to the anti-MuLV p30 polyclonal. Unbound HRP-conjugated secondary antibody is removed during the wash steps, and substrate solution reactive with HRP is added to the wells. A colored product is formed in proportion to the amount of MuLV core antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant MuLV p30 core antigen and sample concentration is then determined.

Description: Our ViraSafe Lentiviral Packaging Systems contain three packaging plasmids for co-transfection with your own third generation lentiviral expression construct. If you need an expression vector as well as the packaging plasmids, consider our ViraSafe Lentiviral Expression Complete Systems. Our Ecotropic Packaging System assembles lentiviruses with an ecotropic envelope protein which will readily infect only mouse and rat cells via receptor-mediated binding, providing an additional level of safety. However, ecotropic viruses are not as stable upon freezing and will not survive ultracentrifugation procedure

Description: Our ViraSafe Lentiviral Packaging Systems contain three packaging plasmids for co-transfection with your own third generation lentiviral expression construct. If you need an expression vector as well as the packaging plasmids, consider our ViraSafe Lentiviral Expression Complete Systems. The Pantropic Packaging System assembles VSVG-pseudotyped lentiviruses which can easily infect virtually any cells regardless of their species of origin.

Description: Clone your gene of interest and a gene-specific promoter into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293T or 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. The RAPAd® Universal Adenoviral Expression System (# VPK-250) contains a promoterless shuttle vector to allow you to insert the promoter of your choice along with your gene of interest to maximize gene expression.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.